检索结果 - Anita K. Wagner
- Showing 1 - 9 results of 9
-
1
-
2
-
3
Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway 由 Mahnum Shahzad, Huseyin Naci, Katharine M. Esselen, Joseph A. Dottino, Anita K. Wagner
出版 2024索引号: 载入...Connect to this object online.
位于: 载入...
图书 -
4
1-year impact of supervision, performance assessment, and recognition strategy (SPARS) on prescribing and dispensing quality in Ugandan health facilities 由 Birna Trap, Moses N. Sembatya, Monica Imi, Morries Seru, Anita K. Wagner, Dennis Ross-Degnan
出版 2020索引号: 载入...Connect to this object online.
位于: 载入...
图书 -
5
-
6
Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020Research in context 由 Yuxuan Wei, Yichen Zhang, Ziyue Xu, Guoan Wang, Yue Zhou, Huangqianyu Li, Luwen Shi, Huseyin Naci, Anita K. Wagner, Xiaodong Guan
出版 2024索引号: 载入...Connect to this object online.
位于: 载入...
图书 -
7
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context 由 Adriana M. Ivama-Brummell, Fernanda L. Marciniuk, Anita K. Wagner, Claudia G.S. Osorio-, Sabine Vogler, Elias Mossialos, Carla L. Tavares-, Huseyin Naci
出版 2023索引号: 载入...Connect to this object online.
位于: 载入...
图书 -
8
Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries 由 Christine Leopold, Aukje K Mantel-Teeuwisse, Sabine Vogler, Silvia Valkova, Kees de Joncheere, Hubert GM Leufkens, Anita K Wagner, Dennis Ross-Degnan, Richard Laing
出版 2014索引号: 载入...Connect to this object online.
位于: 载入...
图书 -
9
Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China 由 Dr. Yu Fang, PhD, Anita K Wagner, DrPH, Shimin Yang, BS, Minghuan Jiang, MS, Fang Zhang, PhD, Dennis Ross-Degnan, ScD
出版 2013索引号: 载入...Connect to this object online.
位于: 载入...
图书